BOSTON, Mass. (TheStreet) -- The year is coming to an end but the biotech calendar is still buzzing with important, stock-moving events right up to New Year's Eve.
Before I get to the calendar, I want to mention some key December biotech catalysts without a fixed date but which investors should still be keeping in mind.
Delcath Systems (DCTH) is supposed to complete the U.S. approval application for its liver tumor Chemosaturation System before the end of the month. RXi Pharmaceuticals (RXII) has promised investors a significant drug development partnership before year's end. Investors will also be eager to hear the outcome of the December meeting between Arena Pharmaceuticals (ARNA) and FDA following the latter's rejection of Arena's obesity drug lorcaserin.
Cell Therapeutics (CTIC) is expecting a ruling on its appeal of the FDA's rejection of the company's lymphoma drug pixantrone. Amgen (AMGN) will announce results from a phase III trial investigating whether treatment with Xgeva can prevent the spread of prostate cancer to the bone. Incyte Pharmaceuticals (INCY) is expected to announce top-line results from a U.S. phase III study of INCB18424 in myelofibrosis.Celgene (CELG) could have data from two important, phase III clinical trials before the books close on 2010: A phase III study of Abraxane in front-line non-small cell lung cancer and a phase III study of Amrubicin in small-cell lung cancer (although this latter study may not be completed until early 2011.) Corcept Therapeutics (CORT) will announce top-line results from a phase III study of Corlux in Cushing's Syndrome during December. Now, to the December biotech calendar: Dec. 2: Affymax (AFFY) provides an update on regulatory plans for the experimental anemia dru Hematide. Exelixis (EXEL) investor/analyst meeting. Targacept (TRGT) investor/analyst meeting. Dec. 3: Orexigen Therapeutics (OREX): FDA should release review documents on the obesity drug Contrave in advance of the advisory panel meeting. Dec. 4-7: American Society of Hematology annual meeting: Important data presentations from Onyx Pharmaceuticals (ONXX), Seattle Genetics (SGEN), Celgene, and others. Dec. 5-9: American College of Neuropsychopharmacology (ACNP) annual meeting. Dec. 7: Orexigen Therapeutics: FDA advisory panel reviewing the obesity drug Contrave. [I'll be live-blogging the Contrave panel, sign up below for an email reminder.] Dec. 8-12: San Antonio Breast Cancer Symposium
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV